

REVIEW

Open Access



Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Daixi Ren^{1,2,3†}, Yuze Hua^{1,2,3†}, Boyao Yu^{1,2,3†}, Xin Ye², Ziheng He², Chunwei Li², Jie Wang², Yongzhen Mo², Xiaoxu Wei², Yunhua Chen², Yujuan Zhou¹, Qianjin Liao¹, Hui Wang¹, Bo Xiang^{1,2,3}, Ming Zhou^{1,2,3}, Xiaoling Li^{1,2,3}, Guiyuan Li^{1,2,3}, Yong Li⁴, Zhaoyang Zeng^{1,2,3} and Wei Xiong^{1,2,3*} 

Abstract

Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a variety of tumors, but resistance during treatment is a major issue. In this review, we describe the utility of PD-L1 expression levels, mutation burden, immune cell infiltration, and immune cell function for predicting the efficacy of PD-1/PD-L1 blockade therapy. Furthermore, we explore the mechanisms underlying immunotherapy resistance caused by PD-L1 expression on tumor cells, T cell dysfunction, and T cell exhaustion. Based on these mechanisms, we propose combination therapeutic strategies. We emphasize the importance of patient-specific treatment plans to reduce the economic burden and prolong the life of patients. The predictive indicators, resistance mechanisms, and combination therapies described in this review provide a basis for improved precision medicine.

Keywords: Cancer immunotherapy, Immune checkpoint blockade, PD-1/PD-L1, Immune cells, Precision medicine

Background

Immunotherapy for cancer has unique advantages, including its precision and minimal side effects [1]. Tumor immunotherapy aims to eliminate tumors by enhancing the body's own immunity. Tumors, on the other hand, evade attack by the immune system through a series of mechanisms known as "immune escape" [2]. The B7 family member, B7-H1 (PD-L1), plays an important role in this process [3–5]. PD-1, an immune checkpoint protein on T cells, binds to PD-L1 on tumor cells, promoting immune escape [6–8]. PD-1/PD-L1 blockade was a major breakthrough

in cancer therapy. However, in many tumors, including non-small-cell lung cancer (NSCLC), renal cell cancer (RCC), and melanoma, PD-1/PD-L1 blockade therapy is only effective in a small proportion of patients [9]. Most patients do not respond to anti-PD-1 therapy (primary resistance), exhibit some initial sensitivity (adaptive resistance), or acquire resistance after relapse [10]; for example, one-quarter to one-third of patients with melanoma exhibit relapse and do not respond well to treatment (Table 1) [11]. Accordingly, resistance is a major limitation of anti-PD-1 therapy in clinical practice. To facilitate precision medicine and burden reduction in patients, we provide examples of curative effect biomarkers and resistance mechanisms against anti-PD-1 therapy. We further discuss combined treatments with the potential to improve efficacy.

* Correspondence: xiongwei@csu.edu.cn

†Daixi Ren, Yuze Hua and Boyao Yu contributed equally to this work.

¹NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China

²Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medical Science, Central South University, Changsha, Hunan, China

Full list of author information is available at the end of the article



Table 1 Representative FDA-approved immunological checkpoint inhibitors

Generic name	Trade name	Target	Application
pembrolizumab	Keytruda	PD-1	melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, microsatellite instability-high cancer, gastric cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, urothelial carcinoma
nivolumab	Opdivo	PD-1	metastatic small cell lung cancer, metastatic melanoma, metastatic urothelial carcinoma, metastatic colorectal cancer, hepatocellular carcinoma, metastatic nonsmall cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, metastatic squamous cell carcinoma of the head and neck
ipilimumab	Yervoy	CTLA-4	advanced renal cell carcinoma, adult and pediatric microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, cutaneous melanoma, unresectable or metastatic melanoma
atezolizumab	Tecentriq	PD-L1	urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer
avelumab	Bavencio	PD-L1	metastatic Merkel cell carcinoma, locally advanced or metastatic urothelial carcinoma [10]

Predictive biomarkers of the efficacy of PD-1 blockade therapy

PD-1/PD-L1 expression

The combination of PD-1 and PD-L1 often leads to tumor immune escape [12]. Inhibiting immune suppression mediated by the PD-1 pathway is the basic principle of anti-PD-1/PD-L1 therapy. PD-L1 expression on tumor cells has high predictive value in melanoma and NSCLC and significance in angiosarcoma [13, 14]. In gastric cancer with high microsatellite instability (MSI-H), PD-L1 expression by immune cells is an important indicator of overall survival (OS) [15]. Decitabine improves the efficacy of anti-PD-1 therapy because PD-L1 in lung cancer cells is increased by IFN [16]. However, PD-L1 has the opposite effect when it exceeds a certain threshold; aromatic hydrocarbon receptor-induced PD-L1 overexpression in NSCLC reduces the efficacy of anti-PD-1 [17]. Valentinuzzi et al. found that patients with melanoma and moderate PD-L1 expression have the best response to anti-PD-1 therapy [18]. Furthermore, PD-1/PD-L1 levels may predict the efficacy of radiotherapy in head and neck cancers [19].

However, quantitative detection of PD-L1 as a prediction index requires antibodies and staining platforms [20–22], which contribute to differences in the accuracy of PD-L1 levels and may affect predictive value.

Antigen recognition initiates the immune response

The activation of adaptive immunity requires antigen recognition. Therefore, increased antigen recognition indicates a more active immune response [23]. The main predictors are MSI and tumor mutation burden (TMB).

Defective DNA mismatch repair (MMR) can cause MSI [24]. High MSI is associated with increased neoantigen production by tumors, greater immunogenicity, and stronger immune response. MSI is an excellent predictive biomarker, and the FDA has approved pembrolizumab to treat unresectable solid tumors with MSI-H or MMR defects (MMR-D) [25]. MSI frequency can also be used for tumor typing [26].

In a clinical trial of recurrent or metastatic colorectal cancer (CRC), patients with high MMR/MSI had better responses to immune checkpoint blockade [27]. MMR-D induction can reverse immunotherapy resistance in patients with pancreatic ductal adenocarcinoma [28]. The difference in MSI and the mutation load caused by MMR-D may explain differences in immunotherapy response. Efficacy is also related to the insertion-deletion mutation burden [29].

TMB, the total number of mutations per megabase in coding regions of tumor cells, is another predictor of therapeutic efficacy [30–32]. Patients with MSI-H tend to have a high TMB, and both parameters reflect instability in tumor cells. Whole exome sequencing can be used to measure exonic mutations in tumor cells comprehensively [33]. Keiichi et al. found that targeted genome sequencing can also be used to measure TMB [34]. TMB and other markers, including frameshifts and PD-L1 expression, are frequently used in clinical settings due to their strong correlation with anti-PD-L1/PD-1 drug effectiveness [35–39]. In intrahepatic cholangiocarcinoma with poor prognosis, patients with high TMB can even achieve complete remission with anti-PD-1 [40]. High TMB may indicate that new neoantigens can be produced by tumor cells to activate T cells suppressed by immune checkpoints [41, 42].

Similar to MMR proteins, POLE can repair errors caused by DNA replication. Mutant POLE is more easily detected by the immune system. Patients with endometrial carcinoma and POLE mutations have improved responses to treatment, and the POLE mutant subtype has better predictive value than the MSI subtype [43, 44]. However, effective methods to predict POLE mutations are needed.

Functional status of immune cells is related to anti-tumor immunity

Cytokines play important roles in the differentiation, maturation, and migration of various immune cells. Cytokine detection has predictive value for PD-1/PD-L1 therapy efficacy. Interferons and other cytokines are

involved in killing or inhibiting tumor cells. TGF- β can inhibit the anti-tumor immune response and promote tumor cell escape. The blocking of TGF- β signaling can reverse insensitivity to anti-PD-1 therapy in CRC and prevent metastasis [45]. Similar results have been seen in bladder cancer [46]. Additionally, IFN- γ up-regulates major histocompatibility complex (MHC) II in antigen-presenting cells (APCs), enhances the production of CTLs, and up-regulates PD-L1 expression in tumor cells [47]. Its effects may be achieved via the JAK-STAT pathway [48]. IFN- γ is indispensable for anti-PD-1 treatment due to its role in the fragility of Tregs [49, 50]. Increased IFN can improve the efficacy of anti-pd-1 therapy [51]. High IFN- γ levels predict improved response to anti-PD-1 therapy in NSCLC [52]. Moreover, deficiency of IFN- signaling may cause tumor cells to resist other immune checkpoints [53]. Accordingly, IFN- γ levels may be used to screen patients who are likely to benefit from anti-PD-1 inhibitors.

Immunotherapy affects various cell and protein levels in the blood. These changes indicate immune cell status, which can predict the efficacy of immunotherapy. Significant changes in the percentage of KI-67⁺ cells among peripheral blood PD-1⁺CD8⁺ T cells predict long-lasting clinical benefits and prolonged progression-free survival in patients with thymic epithelial tumors [54]. Patients with melanoma and high C-reactive protein and absolute neutrophil counts (ANC) have a good response to treatment, and both parameters decrease after treatment [55]. However, unlike C-reactive protein levels, high ANC levels are not associated with better outcomes based on a large-scale analysis of clinical samples; when it exceeds a certain value (>8000), prognosis is poor [56]. However, another study showed that reduced ANC after treatment is associated with cancer control [57]. The neutrophil-to-lymphocyte ratio (NLR) is often used to predict immunotherapy efficacy, and a lower baseline NLR is associated with better prognosis in patients with NSCLC and melanoma treated with nivolumab [56, 57]. Additional clinical trials are needed to identify predictive biomarkers in the blood.

Infiltration of immune cells in the tumor microenvironment is a prerequisite for anti-tumor immunity

Activated T cell recruitment to tumor sites is necessary for their function in tumor cell killing. The efficacy of anti-PD-1 immunotherapy can be predicted according to the degree of immune cells infiltration, determined by two main factors: (1) chemokines (e.g., CCR5, CXCR3, CX3CR1, and CXCR6 are related to the migration of CTLs to tumor sites) and (2) entry through tumor blood vessels.

Tumor-infiltrating lymphocytes (TILs) differ from normal peripheral blood immune cells with respect to surface molecule expression, subtypes, and CD4⁺ and CD8⁺ T cell populations. PD-L1 expression differs significantly among tumors and is correlated with the distribution of invasive immune cells [58–61]. PD-L1 expression is positively correlated with TIL density in esophageal squamous cell carcinoma [62]. Anti-PD-1 therapy may be related to the degree of tumor-invasive immune cell infiltration, and an increase in local T cells can enhance anti-cancer effects [63]. High-density invasive CD8⁺ T cells are associated with prolonged OS in GC and CRC with ovarian metastases [64]. Induced T cell proliferation can relieve non-response to anti-PD-1 or PD-L1 therapy in pancreatic ductal adenocarcinoma [65]. In heterotypic tumor-stroma spheroids, the effect of blocking PD-1 can be increased by increasing TILs [66]. In limited clear cell RCC, two infiltrating T cell subtypes may be used to screen patients who may benefit from immunotherapy [67]. Recently, 37 genes in tumor-associated macrophages that differed between breast cancer tissues and healthy controls were candidate loci for predicting survival [68]. Interestingly, Jin et al. found that CD3⁺ T cells exhibit greater infiltration in PD-1⁺ tumors with MSI in Signet ring cell carcinoma, suggesting that there is a positive correlation between MSI and TILs [69]. Furthermore, EC with POLE mutations and MSI has more neoantigen and T cell infiltration, further demonstrating the association between these indicators and their value in predicting PD-1/PD-L1 blockade efficacy [44, 70].

IDO1, another immune checkpoint protein, promotes the catabolism of tryptophan to inhibit T cells [71]. And IDO1 may be related to T cell infiltration [72]. Furthermore, anti-tumor T cells can be suppressed by Tregs and myeloid-derived suppressor cells (MDSCs) via IDO1, promoting tumor immune evasion [73]. In GIST and soft tissue sarcoma, activation of the IDO1 pathway causes immune suppression, decreasing the efficacy of anti-PD-1 therapy [74]. IDO1 has predictive value in some tumors and can be used to stratify and define some cancers [72, 75, 76]. These findings suggest that IDO1 is a good predictive biomarker and a new approach to cancer treatment (Fig. 1).

Intestinal microbial flora affects host immune function

The intestinal microbiome plays a role in PD-1 blockade therapy. Bactericides can alter the effectiveness of anti-CTLA-4 treatment for melanoma [77]. Jin et al. found a strong correlation between the diversity of the intestinal microbiome and anti-PD-1 in advanced NSCLC. The gut microbiome may improve prognosis by increasing peripheral T and NK cells. Patients with melanoma and particular intestinal microbiome components may

response to immunotherapy in mice given oral bacterial supplementation [80]. Further research should focus on the detection of microbial taxa in the gastrointestinal tract with predictive value for anti-PD-1 responses and the use of fecal transplantation as an adjunct therapy.

Mechanism underlying resistance to PD-1/PD-L1 blockade *T cell dysfunction-mediated resistance*

Various processes, including recognition, activation, differentiation, and chemotaxis, are needed for T cells immune function. The disruption of one or several of these processes leads to T cell dysfunction and tumor immune escape. First, initial T cells must successfully identify tumor antigens presented by APCs. Next, the activation of primary T cells requires the antigen-MHC complex and the binding of B7 and CD28 on the cell surface, providing an important second signal. Finally, differentiated T cells migrate to specific tissues to perform immune functions and contribute to PD-1 blockade therapy resistance.


Antigen recognition disorders

Mutations in beta-2-microglobulin (B2M) disrupt antigen presentation, leading to immune checkpoint blockade therapy resistance. The deletion of B2M in animal models results in the deletion of HLA1 molecules, and approximately 29.4% of patients with progressive drug-resistant diseases have B2M abnormalities in clinical practice. Various mutations can result in a lack of tumor-specific B2M,

especially a loss of heterozygosity. The B2M protein is an irreplaceable HLA1 molecule, and a lack of B2M negatively affects tumor antigen presentation and contributes to resistance to anti-PD-1 therapy [85–87]. Moreover, an increase in PD-1⁺ T cell infiltration is significantly correlated with an increase in B2M mutations, indicating that drug resistance caused by B2M mutation is associated with PD-1⁺ T cell infiltration [88]. In addition to B2M mutations, limited antigen presentation is related to the autonomous expression of MHCII. In MHCII⁺ tumor microenvironments, the infiltration of CD4⁺ T cells increases and LAG3 (an MHCII inhibitory receptor)-induced TIL expression increases, thereby limiting antigen presentation and promoting resistance to anti-PD-1 therapy (Fig. 2) [89, 90].

T cell activation disorders


Shayan et al. found that after blocking PD-1/PD-L1, TIM-3 expression, another immune checkpoint, is upregulated, inhibiting the activation of T cells by inhibiting the phosphorylation of AKT/S6, leading to a decreased immunotherapeutic response [91]. TNF is essential for the expression of TIM-3 in TILs, and its compensatory expression is upregulated after blocking PD-1, thereby inducing TIM-3 expression [92]. In melanoma, anti-PD-1 treatment also increases the inhibitory immune checkpoint, VISTA, that synergistically inhibits T cell activation with PD-L1, leading to adaptive resistance; its expression is higher than that of PD-L1 in CRC [93].



Furthermore, changes in specific genes can also cause T cell activation disorders. Up to one-third of melanomas are accompanied by PTEN deletion, for which the mechanisms include gene mutations and deletions, loss of chromatin, loss of heterozygosity, and epigenetic changes such as hypermethylation-induced transcriptional silencing [94–100]. PTEN itself negatively regulates the PI3K/AKT pathway and down-regulates PD-L1 expression. In melanoma, PTEN deletion promotes AKT phosphorylation, thereby promoting PI3K/AKT pathway activation, and ultimately promotes PD-L1 expression, thereby inactivating T cells. Additionally, PTEN inhibits the expression of immunosuppressive factors IL-10, IL-16, and VEGF through the PI3K/AKT-dependent pathway, and its deletion promotes the activation of the PI3K/AKT pathway, thereby activating STAT3 and eventually increasing IL-10, IL-16, VEGF, and CCL2. Meanwhile, PTEN inhibits the production of the proinflammatory cytokine IL-12 by dendritic cells, forming a suppressive immune microenvironment that inhibits the activation of T cells [94, 101]. In glial tumors and glioblastomas, PTEN deletion activates the PI3K/AKT-mTOR pathway by promoting the activation of ribosomal protein S6 kinase β -1 (S6K1), thereby

promoting PD-L1 translation. Thus, PTEN deletion also deactivates T cells [102].

When PTEN is silenced, PI3K pathway blockade can reduce the activation of AKT, thereby relieving resistance to anti-PD-1 therapy [94]. The blockade of PD-1/PD-L1 results in the adaptive reprogramming of genes in the tumor immune microenvironment, where the up-regulation of CD38 on T cell surfaces leads to resistance [103]. CD38 activation of adenosine receptors by all-trans-retinoic acid (ATRA) inhibits T cell function via adenosine expression [103]. Because adenosine is a strong immunosuppressive substance, it inhibits effector T cell immune function by cytokine secretion and inhibits T cell proliferation [104]. CD73 binding to adenosine receptor 2A on T cells produces adenosine, inhibiting the immune response to PD-1/PD-L1 blockade [105]. Some interleukins have a negative regulatory role in T cell function. IL-35 inhibits the expression of cytotoxic genes in CD8⁺ T cells and reduces cytolytic and noncytolytic functions [106]. Recent studies have shown that the Notch signaling pathway may inhibit FASL and perforin, resulting in decreased activity and dysfunction of CD8⁺ T cells (Fig. 3) [107].




Decrease in T cell infiltration


A decrease in effector T cells in the tumor microenvironment also contributes to resistance to anti-PD-1 therapy. Tumors are characterized by the upregulation of IL-6, granulocyte colony-stimulating factor (G-CSF), and CLCX1 by increasing IL-17A expression. IL-6 promotes tumor proliferation. G-CSF increases tumor-associated neutrophils and decreases CD4⁺ and CD8⁺ T cells in the tumor microenvironment. IL-17A⁺ tumor tissues are also significantly less reactive to PD-1 antibodies in clinical samples [108]. Additionally, the absence of PTEN increases VEGF expression. Elevated VEGF promotes abnormal tumor angiogenesis, which reduces perfusion in blood vessels, causing a hypoxic environment and inhibiting T cell infiltration [109–112]. Therefore, the absence of PTEN may reduce the infiltration of CD8⁺ T cells by upregulating VEGF, leading to resistance to PD-1 therapy [94]. MDSCs are negatively correlated with CD4⁺ and CD8⁺ T cell infiltration and are an important factor in decreased T cell infiltration [113]. Additionally, the presence of immunosuppressive tumor stroma, especially in some solid tumors, makes it difficult for T cells to infiltrate, limiting the efficacy of PD-1 blockade immunotherapy. Irreversible electroporation of the tumor

matrix can address this issue [114]. Therefore, immunosuppressive tumor stroma should be studied further (Fig. 4).

T cell depletion leads to resistance to PD-1 blockade therapy

T cells play a major role in tumor immunity but, in long-term diseases, the dysregulation of T cell subsets or decreases in mature T cells can occur, known as “T cell depletion” [115]. Many mechanisms explain this process, including increased co-inhibitory receptors on T cell surfaces and epigenetic changes in memory T cells. In anti-tumor immunity, chronic persistent type II interferon signaling enables STAT1 tumor-related epigenetic changes, resulting in increased expression of interferon-stimulated genes and inhibitory receptors (TCIRs) on multiple T cells, including *LGALS9* (Galectin-9), MHCII ligands, and immune inhibitory checkpoints, including TIM3 and LAG3. Increased co-expression of multiple TCIRs aggravates T cell depletion. Blocking interferons can reverse resistance caused by T cell depletion [116]. Konen and others have found that NTRK is upregulated by anti-PD-1 therapy. NTRK abnormally activates the JAK-STAT signaling pathway, upregulates the expression of multiple





inhibitory receptors on T cell surfaces, including PD-1, and promotes T cell depletion [117]. Tregs also promote the expression of CD8⁺ T cell depletion-related gene expression via IL-10 and IL-35. Sawant et al. found that IL-10 regulates the STAT pathway and IL-35 regulates the STAT1/4 pathway, further altering the expression of BLIMP1 and its target genes. BLIMP1 enhances the expression of inhibitory receptors in T cells and promotes T cell depletion (Fig. 5) [118].

Resistance caused by changes in PD-L1 expression

The response to PD-1/PD-L1 blockade therapy is better in tumors with PD-L1-positive expression [9]. Both membrane expression and secretion exosomes containing PD-L1 may contribute to resistance. PD-1 blockade therapy can result in the upregulation of PD-L1 expression, causing drug resistance. The insufficient antibodies do not completely block PD-1/PD-L1. Conversely, low

PD-L1 expression reduces therapeutic efficacy; this may be explained by other immune escape mechanisms.


The JAK/STAT pathway is critical for PD-L1 expression and drug resistance [119–121]. Because JAK/STAT up-regulates the expression of PD-L1, it also plays an important role in tumor antigen expression. JAK1 is essential for both IFN- γ -mediated immune responses and MHC I/II expression, whereas JAK2 contributes to IFN- γ -induced STAT5 phosphorylation and PD-L1 expression, and mutations disrupt antigen presentation [122]. In addition to the JAK/STAT pathway, other factors cause changes in PD-L1 expression. In large B lymphoma, miR155 binds to the 3'-UTR of PD-L1 to increase its expression and inhibits CD8⁺ T cell activity through the ERK and AKT pathways. Similar effects have been found with miR-142-5p in pancreatic cancer; however, miR-142-5p overexpression inhibits tumor cell PD-L1 expression and enhances tumor immunity [123].

In melanoma, resistance due to JAK1/JAK2 inactivation mutations, leading to recurrence, has been found in a small number of patients [87, 119]. Patients with JAK1/2 mutations can develop drug resistance, irrespective of TMB [124–126]. JAK1/2 regulates the chemokines CXCL9, CXCL10, and CXCL11 [127]. Deletion of the tumor suppressor CDKN2A, one of the most frequently lost tumor suppressor genes in human cancers, increases the likelihood of JAK2 deletion and resistance to immunotherapy [128].

Many factors lead to the adaptive up-regulation of PD-1 and drug resistance. In a mouse model of KP mutant lung cancer, neurotrophic tyrosine receptor kinase 1 (NTRK1) expression increased significantly after treatment with a PD-1 inhibitor, and NTRK1 promoted abnormal JAK1 and STAT3 activation. Excessive JAK/STAT pathway activation leads to PD-L1 up-regulation [117]. In NKT cell lymphoma, after PD-1 blockade, the JAK/STAT pathway is activated via IFN- γ secreted by TILs, promoting PD-L1 expression [48]. In most patients with lung cancer and non-T790M-mediated epidermal growth factor receptor (EGFR) mutations, the downstream JAK/STAT, AKT/mTOR, and mitogen-activated protein kinase (MAPK)1 pathways are not activated, resulting in unexpressed PD-L1 and resistance to PD-1

blockade therapy [129–135]. However, the JAK pathway also promotes inflammation and other functions in the tumor microenvironment [136]. We cannot rule out the effects of the inflammatory response on PD-L1 and therapeutic efficacy. Mutations in the serine/threonine-protein kinase gene, *BRAF*, in tumors also increase PD-L1 expression and induce drug resistance involving tumor stromal cells. *BRAF* mutations also lead to constitutive activation of the MAPK pathway, enhance the oncogenic activity, increase invasiveness and metastasis, and cause resistance [137].

PD-L1 exosomes have been detected in a variety of cancers, including melanoma and head and neck cancer [119, 138]. High IFN- γ levels are associated with drug resistance [119]. Other studies have shown that the increase in PD-L1 is mainly due to exosomes, rather than membrane expression. Exosomes may even induce the expression of T cell depletion markers. Immunotherapy results in TNF- α production and T cell accumulation in tumors, promotes histone methylase EZH2 activity in melanoma, decreases immunogenicity, silences antigen-presentation, and up-regulates PD-L1 expression. After the inactivation of EZH2, resistance is reversed by the continuous aggregation of CD8⁺ T cells with low PD-1 and IFN- γ levels [139]. In lung adenocarcinoma, EZH2-



positive patients show high PD-L1 expression [140]. In mice, TNF can promote EZH2 expression in tumor cells and trigger tumor recurrence [92, 141]. In patients with metastatic melanoma treated with PD-1, TNF expression is increased, and there is a strong positive correlation between TNF and *PDCD1LG1* (encoding PD-L1). TNF- α increases PD-L1 stability by activating COP9 signal 5 [142].

PD-L1 also has a direct effect on tumors. It binds to the surfaces of tumor cells via integrin-binding β 4 (ITGB4) and activates the protein kinase/GSK3 β signaling pathway, thereby inducing the transcriptional repression of *SNAI1*. *SNAI1* regulates *SIRT3*, epithelial-mesenchymal transition-related genes, and glucose metabolism and promotes lymphatic metastasis. That is, PD-L1 promotes tumor growth and metastasis via ITGB4/*SNAI1*/*SIRT3* signaling, and this is one of the main causes of PD-L1 resistance [143]. This suggests that targeting PD-1/PD-L1 in combination with downstream factors, including ITGB4, can enhance the immunological efficacy of PD-1/PD-L1 (Fig. 6).

Combination therapy to improve the efficacy of PD-1/PD-L1 blockade

Based on the aforementioned mechanisms underlying resistance to PD-1 blockade therapy, we explore candidate targets for combined PD-1 immunotherapy, providing new hope for improving the therapeutic efficacy through increasing T cell proliferation and enhancing immune cell function.

Combination therapeutic strategies to enhance T cell activation

Two strategies can enhance T cell activation: enhancing tumor immunogenicity and enhancing the activation of co-stimulatory signals on primitive and memory T cells.

The induction of immunogenic cell death (ICD) has been proposed as an effective way to enhance tumor immunogenicity. Dying tumor cells can express or release extensive immunostimulation damage-associated molecular patterns. This process also releases high mobility box 1 (HMGB1) and ATP to attract and activate APCs. Calreticulin on the surface of dead cells transmits an 'eat-me' signal to phagocytic cells to activate macrophages, ultimately leading to enhanced tumor immunogenicity and immune responses. There is a significant synergistic effect between the induction of ICD and PD-1 blockade [144–148]. In addition to ICD, Kim et al. suggested that the restoration of the function of the tumor suppressor p53 can also enhance tumor cell immunogenicity, thereby enhancing the innate and adaptive immune response and counteracting tumor-induced immunosuppression. Additionally, heterogeneous hypersensitivity reactions associated with PD-1 antibodies are

alleviated, which can alleviate the side effects of PD-1 treatment [149–153].

Various molecules that enhance co-stimulatory signaling for T cell activation have been identified. Chimeric antigen receptor T cells edited by the CRISPR/Cas9 gene directed against the B2M mutation proposed above can significantly increase anti-tumor activity [154].

Inhibitor of apoptosis protein (IAP) has extensive biological functions, including the regulation of migration, apoptosis, and signal transduction and the promotion of inflammation. IAP antagonists, including Smac mimetics, can enhance the activation and proliferation of effector T cells by enhancing CD3/CD28 co-stimulation [107]. Additionally, bone marrow-derived hematopoietic stem cells expressing type 2 C-C chemokine receptor (CCR2⁺ HSCs) preferentially migrate to tumor tissues and differentiate into APCs in the tumor microenvironment. The presentation of tumor-derived antigens to CD8⁺ T cells overcomes resistance to PD-1 checkpoint blockade [155]. Histone deacetylases (HDAC) are a therapeutic target for a variety of cancers. The inhibition of HDAC6 activates the AKT/mTOR/p65 pathway and up-regulates BCL-6, Eomes, HIF-1, and T-bet, thereby increasing the expression of co-stimulatory molecules (CD28, 41bb, CD40L, OX40, and CD38) and activation of antigen-specific memory T cells [156]. B-type TILs are good prognostic markers for most cancers [157]. Soldvilla et al. proposed that the injection of activated B lymphocytes in combination with anti-PD-1 agents could improve therapeutic efficacy. Combined with anti-PD-1 treatment, it is possible to provide multiple costimulatory ligands in the tumor and activate the systemic anti-tumor immune response, with superior anti-tumor effects (Fig. 7) [158].

Combination therapeutic strategy to enhance T immune cell function and infiltration

Activated T cells need to infiltrate the tumor tissue to exert anti-tumor effects, alone or in combination with other immune cells. We next discuss factors that increase the density of T cells in tumor tissues and enhance immune cell function.

The inflammatory response increases following IAP blockade, thereby stimulating CTLs and mononuclear/macrophage TNF production and enhancing tumor cell killing [107]. Blocking IAP acts synergistically with anti-PD-1 treatment to enhance anti-tumor immunity. In addition to IAP, IL-15, CD96, CD47, and CD137 affect immune cell activity and have potential therapeutic applications. When IL-15 is activated, the number and activity of CD8⁺ T and NK cells increase [159]. CD96 regulates the effects of NK cells and metastasis. CD96-deficient CD8⁺ T cells are superior to CD96-sufficient CD8⁺ T cells at suppressing tumors, and the co-expression of CD96

(See figure on previous page.)

Fig. 7 Combination therapeutic strategy to enhance T cell activation and T immune cell function and infiltration. There are approximately five types of combined treatment strategies. Combinations with anti-PD-1/PD-L1 agents can induce better therapeutic effects by inducing immunogenic cell death and restoring the function of the tumor suppressor p53. We summarize the combinations with B2M, HSCs (CCR2+), HDAC, and other cells and molecules. We describe a number of ways to inhibit MDSCs and thereby enhance therapeutic efficacy. Various molecules, including IL-15, CD96, CD47, and CD137 have potential inhibitory effects. We also summarize receptor-mediated and combination therapeutic strategies for the activation of inflammatory pathways and immune cells

and PD-1 has been detected in both mouse and human TILs, suggesting an immune-inhibitory effect. Blocking CD96 can significantly enhance the interaction between NK and T cells and increase their anti-tumor effect [160]. Blocking CD47 also increases the reactivity of anti-tumor T and NK cells and increases the release of various cytokines, including IFN- γ and IL-6. Moreover, the simultaneous blocking of CD47 and PD-1 can further prevent the immune escape of circulating tumor cell subsets, thereby inhibiting metastasis [161, 162]. Rodríguez-Ruiz et al. proposed that combined anti-PD1 and anti-CD137 treatment increases granzyme-B secreted by CTLs, indicating an improved cytotoxic effect [163]. RANKL, which blocks NF- κ B ligands, can increase the anti-metastatic activity of antibodies targeting PD1/PD-L1, and the combination of anti-PD1 and anti-RANKL agents can recruit NK cells to promote the synergy between NK cells and TILs. This increases the secretion of interferon and tumor killing factors [164]. Low PD-L1 expression is also a major cause of poor PD-1 blocking; accordingly, co-inhibitory receptors are a promising area of research. The newly discovered T cell B7 family immune checkpoint, HHLA2, is a co-therapeutic target for PD-L1, improving the number and activity of T cells in the tumor microenvironment [165]. Another co-inhibitory receptor, KLRG1, expressed on late-differentiated effector cells and CD8⁺ T and NK cells, is up-regulated in treated tumor samples, resulting in drug resistance; blocking both KLRG1 and PD-1 can improve outcomes [166]. However, more potent co-inhibitory receptor blockade may not result in a better therapeutic effect. Pai et al. found that combination therapy targeting PD-1 and CTLA-4 induces an excess of IFN- γ and leads to drug resistance. Excess IFN- γ increases IDO and PD-L1 expression. There is a threshold for co-inhibitory receptor blocking, beyond which the effects are reversed [167]. This deserves further exploration, and the dose range for combination therapy should be optimized.

MDSC proliferation is another cause of tumor immune escape. This limits the efficacy of PD-1/PD-L1 blockade. The generation and migration of MDSCs are regulated by multiple chemokines. It is essential to inhibit MDSC proliferation and migration to the tumor microenvironment while blocking PD-1. In children with metastatic sarcoma, the efficacy of PD-1 blockade therapy was significantly improved by treatment with an anti-CXCR2 monoclonal antibody [168]. CCL2 is positively correlated with MDSCs

in tumor tissues, suggesting that it promotes MDSC migration to tumor tissues. In tumor-bearing mice, CCL2 expression is significantly increased in the blood and tumor tissues. Anti-CCL2 treatment inhibits the expression of arginase 1 and iNOS, thereby reducing G-MDSC and M-MDSC in and around the tumor. Combination therapy can increase CD4⁺ and CD8⁺ T cell infiltration and prolong the survival of tumor-bearing mice [169]. Furthermore, the inhibition of HDAC6 significantly reduces HLA-DR-Low/CD11b⁺CD33⁺ MDSCs in the tumor microenvironment [156]. The chemokine CXCL12, an immunosuppressive molecule, combined with clinical-stage I-RNA-aptamer NOX-A12, increases the infiltration of T and NK cells in solid tumors [66].

The inhibition of PIM kinase may address the T cell depletion issue. PIM kinases are a family of serine/threonine kinases that promote cell cycle transition, cell growth, mTORC1 activity, and the ability of T cells to inhibit tumors. PIM kinase inhibition upregulates the expression of genes involved in the inhibition of glycolysis and reduces CD38 expression in negatively regulated T cell metabolism. The inhibition of PIM can increase the tolerance and persistence of T cells in the tumor microenvironment, and the combined effect with blocking PD-1 can significantly improve efficacy (Fig. 7) [170].

Combination therapeutic strategy for combined chemoradiotherapy

In addition to the above-mentioned proposed strategies to enhance efficacy, we must also discuss chemoradiotherapy combined with anti-PD1 immunotherapy, which has been implemented in clinical practice. Clinical trials have shown that this strategy have achieved satisfactory results in NSCLC, gastric, (triple-negative) breast, recurrent nasopharyngeal, and rectal cancers, hematological malignancies, and other tumors [171–178]. The combined effects of chemoradiotherapy are due to the enhanced immunogenicity of tumor cells, antigen presentation, and recognition of tumor cells by T cells. Chemoradiation increases the tumor mutation load and exposes antigens [179]. Simultaneously, the tumor microenvironment becomes more conducive to anti-tumor immunity. On the one hand, there are changes in cellular components in the microenvironment, including increased inflammatory cells and decreased MDSCs

Table 2 Combinations of immunological checkpoint inhibitors in US clinical trials

Immunological checkpoint inhibitor	Combined drug	Application	Number of volunteers	OS (months)	Rate of OS (at 6 months)	ORR (%)	DOR (months)	PFS (months)
pembrolizumab	Epacadostat [168]	Unresectable or metastatic melanoma	354	–	84.1	34.2	–	4.70
	Pomalidomide+Dexamethasone [169]	Refractory or relapsed and refractory multiple myeloma	126	21.0 (14.2-NA)	–	–	–	5.7
nivolumab	Ipilimumab [170, 171]	Previously untreated advanced melanoma	313	–	0.86	57.6	–	11.50
		Previously untreated advanced or metastatic renal cell carcinoma	550	–	–	38.7	–	12.42
ipilimumab	Sargramostim [172]	stage III or stage IV melanoma untreatable by surgery	123	17.5 (14.9-NA)	–	–	–	3.10
		untreated unresectable stage III or IV melanoma	250	11.17	–	–	19.3	2.76
atezolizumab	Nab-Paclitaxel + Carboplatin [175] Carboplatin + Etoposide [176]	Lung cancer—non small cell squamous	388	13.37	–	–	–	5.55
		Non-squamous non-Small cell lung cancer	483	18.6	–	–	–	7.00
pembrolizumab	Cobimetinib [177] Bevacizumab [178]	Untreated extensive-stage small cell lung cancer	201	12.3	–	–	–	5.2
		Metastatic colorectal adenocarcinoma	183	8.87	–	–	1.97	1.91
		Renal cell carcinoma	178	–	–	–	–	8.90

[180]. On the other hand, radiotherapy can cause changes in gene expression in various cells in the tumor microenvironment. Some studies have found that radiation induces upregulation of MHC1, intercellular adhesion molecule 1 (ICAM-1), NKG2D ligand (NKG2DL), death receptor Fas, and costimulatory molecule CD80 on tumor cells, which enhances both antigen presentation and T cell recognition [181]. Other studies have found that in NSCLC, radiotherapy can adaptively increase the expression of PD-L in tumor cells. This may also be one of the mechanisms [171]. However, two clinical trials have shown that PD-1 immunotherapy after radiation therapy can cause an excessive immune response, as seen in the adverse effects of combination therapy in obesity-related malignancies, including esophageal adenocarcinoma [182, 183]. This may be because the relationship between radiation and the immune system is complex and multifactorial, and is related to the dose and type of radiation and the type of immune cells [181]. Furthermore, this process induces an inflammatory response, and different degrees of inflammatory response may lead to different outcomes. Therefore, it is essential to clarify the basic combination therapy mechanism further, and the specific scheme and dosage of the combination in the clinic need to be determined (Table 2).

Outlook

Despite the unique advantages of tumor immunotherapy demonstrated by recent research, this approach is still highly limited in clinical settings due to drug resistance and high costs. We review common bio-predictive markers and therapies and discuss the molecular mechanisms underlying resistance to PD1/PD-L1 blockade therapy. Based on these mechanisms, we describe promising drugs and potential molecular targets for combination therapy.

Although the biomarkers that can be used for prediction are described above, they still have significant uncertainties in the clinic. Error in predicting PD-L1 expression is mainly related to tumor heterogeneity and differences among the monoclonal antibodies used for detection [23, 184]. At present, IHC is primarily used to measure PD-1 expression; however, other antibodies, including E1L3N, SP142, and SP263, are also used [185]. There is no standard method for quantification, which is a problem that needs to be solved. Morales-Betanzos et al. established a targeted mass spectrometry platform that can quantify the expression of PD-L1. Regarding tumor heterogeneity, the minimum tumor area that can determine the PD-L1 prediction evaluation must be elucidated [186, 187]. The International TILs Working Group provides a standardized method for pre-

treatment tumor TIL testing, comprising a visual assessment of H&E stained sections [188]. Although it has limitations in macrophage detection, it has been widely used in many clinical applications. Furthermore, more practical predictive indicators, such as microbial taxa in the intestines, should be identified in addition to the development of accurate detection methods.

Furthermore, the development of research and detection methods for molecular markers in the blood is of considerable significance because the extraction of peripheral blood for detection has the advantages of being simple and easy to perform and less invasive to the patient. This is an advantage that traditional pathological examinations do not have and should be focused on.

In general, the precise mechanisms underlying drug resistance to PD-1 treatment and appropriate therapeutic strategies are still unclear. Many studies have suggested that high PD-1/PD-L1 expression predicts a good prognosis, but tumors can also develop drug resistance by adaptively up-regulating PD-L1 expression during therapy. The level of PD-L1 is not proportional to the therapeutic effect, and optimal treatment strategies are still needed [167]. We believe that the detection of PD-L1 expression is critical for PD-1 blockade therapy. First, the expression of PD-L1 should be detected to identify whether the tumor is suitable for PD-1 blockade therapy. During treatment, dynamic changes in PD-L1 expression should be detected. Additionally, resistance to PD-1 blockade is caused by exosome PD-L1 secretion. This resistance is caused not only by promoting the expression of PD-L1, but also by the direct binding of PD-L1 exosomes to anti-PD-L1 antibodies. Tumor- and immune-cell-derived PD-L1 exosomes can inhibit tumor progression by promoting antigen presentation and regulating immune function. However, studies are currently focusing on its impact on tumor progression; therefore, the study of exosomes must be more comprehensive [2]. To detect changes in PD-L1 expression and guide precision medicine, more accurate detection methods are needed [189]. More generally, the membrane and exosome expression of PD-L1 should be dynamically monitored. In addition to the effects of PD-L1 expression on drug resistance mechanisms, it has recently been discovered that certain molecular targets already used in cancer treatment also affect the efficacy of immunotherapy, leading to the development of resistance to PD-1/PD-L1 blockade therapy. In addition to TNF- α and IFN- γ mentioned above, there are many inflammatory factors, including IL-6, IL-17, and EGF, that play an important role in the PD-1/PD-L1 signaling pathway, which is in line with the idea that inflammation promotes tumorigenesis as opposed to metastasis. These inflammatory factors have potential effects on tumor immune escape, providing new targets for combined immunotherapy

[182]. As a research hotspot in immunotherapy, neoantigen vaccines have been used to screen and identify highly exogenous neoantigens by sequencing the entire exons of tumor cells to activate immune responses. These neoantigens have also been combined with PD-1/PD-L1 blockade therapy with good effects [172].

The combination of PD-1 and other immune checkpoint blockade is a potentially effective treatment strategy. Increased blockade does not predict a better effect; there is a threshold, after which the opposite effects are observed [189]. In short, the human immune system represents a precise balance among various molecules, immune cells, and effectors. The role of any single pathway cannot be considered in isolation.

In addition to immune checkpoints and immune system activity, synergistic treatment approaches, including strategies to activate tumor cell autophagy, inhibit tumor angiogenesis, and inhibit mesenchymal transition, can also improve the efficacy of PD-1/PD-L1 blockade therapy. We should broaden our thinking to the perspective of the tumor itself, e.g., inhibiting nutrient supply, growth, and metastasis, and consider combined approaches with immunotherapy to achieve better results.

Conclusions

Despite the success of PD-1/PD-L1 treatment, its practical application is still limited. To determine whether a patient may benefit from anti-PD-1 treatment and reduce the burden on patients, PD-1/PD-L1 expression and predictive indicators should be dynamically monitored throughout the treatment process. Established prediction molecules are still insufficient, and improved prediction methods are needed. To address drug resistance, a more systematic research approach should be adopted, beyond studies of particular target molecules. The limits of various drugs and the potential for excessive doses should be considered. Finally, we should actively search for joint treatment strategies to expand the scope and effectiveness of immunotherapy.

Abbreviations

ANC: Absolute Neutrophil Counts; APC: Antigen-Presenting Cell; ATRA: All-Trans-Retinoic Acid; CCR2+ HSCs: Hematopoietic Stem Cells Expressing Type 2 C-C Chemokine Receptor; CRC: Colorectal Cancer; EGFR: Epidermal Growth Factor Receptor; G-CSF: Granulocyte Colony-Stimulating Factor; HDAC: Histone Deacetylase; ICD: Immunogenic Cell Death; MDSC: Myeloid-Derived Suppressor Cell; MHC: Major Histocompatibility Complex; MMR: Mismatch Repair; MMR-D: Mismatch Repair Defects; MSI-H: High Microsatellite Instability; NLR: Neutrophil-to-Lymphocyte Ratio; NSCLC: Non-Small-Cell Lung Cancer; OS: Overall Survival; RCC: Renal Cell Cancer; TCIR: T Cell Inhibitory Receptors; TIL: Tumor-Infiltrating Lymphocytes; TMB: Tumor Mutation Burden

Authors' contributions

DR, YH, BY, XY, ZH, CL, JW, YM, XW, YC collected the related literature and drafted the manuscript. YZ, QL, HW, BX, MZ, XL, GL, YL, ZZ, WX participated in the design of the review and drafted the manuscript. All authors have read and approved the final manuscript.

Funding

This study was supported by grants from The National Natural Science Foundation of China (81672683, 81672993, 81772928, 81872278 and 81972776), the Overseas Expertise Introduction Project for Discipline Innovation (111 Project, No. 111–2–12), and the Natural Science Foundation of Hunan Province (2017SK2105, 2018SK21210 and 2018SK21211).

Availability of data and materials

Not application.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China. ²Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medical Science, Central South University, Changsha, Hunan, China. ³Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China. ⁴Department of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.

Received: 18 September 2019 Accepted: 20 January 2020

Published online: 30 January 2020

References

- Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med*. 2015;373:2425–37.
- Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. *Cell*. 2018;175:313–26.
- Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med*. 2002;8:793–800.
- Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nat Med*. 1999;5:1365–9.
- Jiang XJ, Wang J, Deng XY, Li XL, Li XY, Zeng ZY, et al. Immunotherapy targeted to immune checkpoint: a revolutionary breakthrough in cancer therapy. *Prog Biochem Biophys*. 2018;45:1178–86.
- Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. *Clin Cancer Res*. 2012;18:6580–7.
- Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell*. 2015;27:450–61.
- Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. *Mol Cancer*. 2019;18:10.
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012;366:2443–54.
- Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. *Cell*. 2017;168:707–23.
- Schachter J, Ribas A, Long GV, Arance A, Grob J-J, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet*. 2017;390:1853–62.
- Zhang J, Fang W, Qin T, Yang Y, Hong S, Liang W, et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. *Med Oncol*. 2015;32:86.

13. Carbone L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. *PLoS One*. 2015;10:e0130142.
14. Shimizu A, Kaira K, Okubo Y, Utsumi D, Yasuda M, Asao T, et al. Positive PD-L1 expression predicts worse outcome in cutaneous Angiosarcoma. *J Glob Oncol*. 2017;3:360–9.
15. Cho J, Lee J, Bang H, Kim ST, Park SH, An JY, et al. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. *Oncotarget*. 2017;8:13320–8.
16. Lai Q, Wang H, Li A, Xu Y, Tang L, Chen Q, et al. Decitabine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells. *Oncogene*. 2018;37:2302–12.
17. Wang GZ, Zhang L, Zhao XC, Gao SH, Qu LW, Yu H, et al. The aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. *Nat Commun*. 2019;10:1125.
18. Valentinuzzi D, Simoncic U, Ursic K, Vrankar M, Turk M, Jeraj R. Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. *Phys Med Biol*. 2019;64:025017.
19. Lyu X, Zhang M, Li G, Jiang Y, Qiao Q. PD-1 and PD-L1 expression predicts radiosensitivity and clinical outcomes in head and neck Cancer and is associated with HPV infection. *J Cancer*. 2019;10:937–48.
20. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. *JAMA Oncol*. 2016;2:46–54.
21. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. *JAMA Oncol*. 2017;3:1051–8.
22. Tang Y, He Y, Shi L, Yang L, Wang J, Lian Y, et al. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma. *Oncotarget*. 2017;8:39001–11.
23. Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. *Mol Cancer*. 2019;18:128.
24. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for clonal carcinogenesis. *Nature*. 1993;363:558–61.
25. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clin Cancer Res*. 2019;25:3753–8.
26. Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. *Clin Cancer Res*. 2016;22:813–20.
27. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol*. 2017;18:1182–91.
28. Hu ZI, Hellmann MD, Wolchok JD, Vyas M, Shia J, Stadler ZK, et al. Acquired resistance to immunotherapy in MMR-D pancreatic cancer. *J Immunother Cancer*. 2018;6:127.
29. Mandal R, Samstein RM, Lee KW, Havel JJ, Wang H, Krishna C, et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. *Science*. 2019;364:485–91.
30. Tu C, Zeng Z, Qi P, Li X, Guo C, Xiong F, et al. Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein-Barr virus by whole-genome sequencing. *Carcinogenesis*. 2018;39:1517–28.
31. Tu C, Zeng Z, Qi P, Li X, Yu Z, Guo C, et al. Genome-wide analysis of 18 Epstein-Barr viruses isolated from primary nasopharyngeal carcinoma biopsy specimens. *J Virol*. 2017;91. <https://doi.org/10.1128/JVI.00301-17>.
32. Xiao L, Wei F, Liang F, Li Q, Deng H, Tan S, et al. TSC22D2 identified as a candidate susceptibility gene of multi-cancer pedigree using genome-wide linkage analysis and whole-exome sequencing. *Carcinogenesis*. 2019;40:819–27.
33. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. *Nat Rev Genet*. 2013;14:703–18.
34. Hatakeyama K, Nagashima T, Urakami K, Ohshima K, Serizawa M, Ohnami S, et al. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing. *Biomed Res*. 2018;39:159–67.
35. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. *Science*. 2018;362:eaar3593.
36. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. *Mol Cancer Ther*. 2017;16:2598–608.
37. Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, et al. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. *JCI Insight*. 2018;3:98811.
38. Shrestha R, Prithviraj P, Anaka M, Bridle KR, Crawford DHG, Dhungel B, et al. Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma. *Front Oncol*. 2018;8:269.
39. Yarchoan M, Albacker LA, Hopkins AC, Montesin M, Murugesan K, Vithayathil TT, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. *JCI Insight*. 2019;4:e126908.
40. Mou H, Yu L, Liao Q, Hou X, Wu Y, Cui Q, et al. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. *BMC Cancer*. 2018;18:1105.
41. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*. 2015;348:124–8.
42. Ge J, Wang J, Wang H, Jiang X, Liao Q, Gong Q, et al. The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer. *J Cancer*. 2020;11:932–9.
43. Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. *J Clin Invest*. 2016;126:2334–40.
44. Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileskin L, et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. *Oncimmunology*. 2017;6:e1264565.
45. Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llgero A, Badia-Ramentol J, Iglesias M, et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. *Nature*. 2018;554:538–43.
46. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature*. 2018;554:544–8.
47. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. *Br J Cancer*. 2015;112:1501–9.
48. Xue W, Li W, Zhang T, Li Z, Wang Y, Qiu Y, et al. Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-gamma-associated JAK-STAT pathway. *Onco Targets Ther*. 2019;12:2079–88.
49. Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, et al. Interferon-gamma drives Treg fragility to promote anti-tumor immunity. *Cell*. 2017;169:1130–41 e1111.
50. Wang YA, Li XL, Mo YZ, Fan CM, Tang L, Xiong F, et al. Effects of tumor metabolic microenvironment on regulatory T cells. *Mol Cancer*. 2018;17:168.
51. Jiang X, Wu H, Zhao W, Ding X, You Q, Zhu F, et al. Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. *Cancer Cell Int*. 2019;19:68.
52. Boutsikou E, Domvri K, Hardavella G, Tsiouda D, Zarogoulidis K, Kontakiotis T. Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice. *Ther Adv Med Oncol*. 2018;10:1758835918768238.
53. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-gamma pathway genes in Tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. *Cell*. 2016;167:397–404 e399.
54. Kim KH, Cho J, Ku BM, Koh J, Sun JM, Lee SH, et al. The first-week proliferative response of peripheral blood PD-1(+)/CD8(+) T cells predicts the response to anti-PD-1 therapy in solid tumors. *Clin Cancer Res*. 2019;25:2144–54.
55. Okuhira H, Yamamoto Y, Inaba Y, Kunimoto K, Mikita N, Ikeda T, et al. Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab. *Biosci Trends*. 2018;12:412–8.
56. Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could

- predict overall survival in patients with advanced melanoma treated with nivolumab. *J Immunother Cancer*. 2018;6:74.
57. Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, et al. Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 Axis inhibitors in patients with advanced non-small-cell lung Cancer. *Clin Lung Cancer*. 2018;19:426–34 e421.
58. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. *Clin Cancer Res*. 2014;20:5064–74.
59. Xiong F, Deng S, Huang HB, Li XY, Zhang WL, Liao QJ, et al. Effects and mechanisms of innate immune molecules on inhibiting nasopharyngeal carcinoma. *Chin Med J (Engl)*. 2019;132:749–52.
60. Wu Y, Wei F, Tang L, Liao Q, Wang H, Shi L, et al. Herpesvirus acts with the cytoskeleton and promotes cancer progression. *J Cancer*. 2019;10:2185–93.
61. Jin K, Wang S, Zhang Y, Xia M, Mo Y, Li X, et al. Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis. *Cell Mol Life Sci*. 2019;76:4275–89.
62. Jiang Y, Lo AWI, Wong A, Chen W, Wang Y, Lin L, et al. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. *Oncotarget*. 2017;8:30175–89.
63. Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, et al. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. *Clin Cancer Res*. 2017;23:5514–26.
64. Tai H, Yang Q, Wu Z, Sun S, Cao R, Xi Y, et al. PD-L1 expression predicts a distinct prognosis in Krukenberg tumor with corresponding origins. *J Immunol Res*. 2018;2018:9485285.
65. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. *J Immunother*. 2015;38:1–11.
66. Zboralski D, Hoehlig K, Eulberg D, Fromming A, Vater A. Increasing tumor-infiltrating T cells through inhibition of CXCL12 with NOX-A12 synergizes with PD-1 blockade. *Cancer Immunol Res*. 2017;5:950–6.
67. Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, et al. Tumor-infiltrating and peripheral blood T-cell Immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. *Clin Cancer Res*. 2017;23:4416–28.
68. Cassetta L, Fraggogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. *Cancer Cell*. 2019;35:588–602 e510.
69. Jin S, Xu B, Yu L, Fu Y, Wu H, Fan X, et al. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. *Oncotarget*. 2017;8:38850–62.
70. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e-mutated and microsatellite-unstable endometrial cancers with Neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. *JAMA Oncol*. 2015;1:1319–23.
71. Mondal A, Smith C, DuHadaway JB, Sutanto-Ward E, Prendergast GC, Bravo-Nuevo A, et al. IDO1 is an integral mediator of inflammatory neovascularization. *EBioMedicine*. 2016;14:74–82.
72. Heeren AM, van Dijk I, Berry D, Khelil M, Ferns D, Kole J, et al. Indoleamine 2,3-dioxygenase expression pattern in the tumor microenvironment predicts clinical outcome in early stage cervical Cancer. *Front Immunol*. 2018;9:1598.
73. Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, et al. IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. *Clin Cancer Res*. 2018;24:2559–73.
74. Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, Le Cesne A, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. *JAMA Oncol*. 2018;4:93–7.
75. Duan J, Xie Y, Qu L, Wang L, Zhou S, Wang Y, et al. A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy. *J Immunother Cancer*. 2018;6:100.
76. Zhou S, Zhao L, Liang Z, Liu S, Li Y, Liu S, et al. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression predicts poor pathologic response and recurrence in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. *Cancers (Basel)*. 2019;11: E169.
77. Vetzou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science*. 2015;350:1079–84.
78. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinetz TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science*. 2018;359:97–103.
79. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science*. 2018;359:104–8.
80. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science*. 2018;359:91–7.
81. Kawamoto S, Tran TH, Maruya M, Suzuki K, Doi Y, Tsutsui Y, et al. The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. *Science*. 2012;336:485–9.
82. Park SJ, Kim JH, Song MY, Sung YC, Lee SW, Park Y. PD-1 deficiency protects experimental colitis via alteration of gut microbiota. *BMB Rep*. 2017;50:578–83.
83. Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’. *Histopathology*. 2017;70:558–67.
84. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. *Eur J Cancer*. 2016;60:190–209.
85. Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. *Cancer Discov*. 2017;7:1420–35.
86. Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. *Nat Commun*. 2017;8:1136.
87. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. *N Engl J Med*. 2016;375:819–29.
88. Janikovits J, Muller M, Krzykalla J, Korner S, Echterdiek F, Lahmann B, et al. High numbers of PD-1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer. *Oncoimmunology*. 2018;7:e1390640.
89. Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. *JCI Insight*. 2018;3:120360.
90. Zhou H, Liu T, Wang Z. Analysis of non-small cell lung cancer microenvironment indicates preponderance of T cell exhaustion marker expression. *Exp Cell Res*. 2017;360:205–9.
91. Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. *Oncoimmunology*. 2017;6:e1261779.
92. Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, et al. TNFalpha blockade overcomes resistance to anti-PD-1 in experimental melanoma. *Nat Commun*. 2017;8:2256.
93. Xie S, Huang J, Qiao Q, Zang W, Hong S, Tan H, et al. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. *Cancer Immunol Immunother*. 2018;67:1685–94.
94. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. *Cancer Discov*. 2016;6:202–16.
95. Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. *Genes Dev*. 2012;26:1055–69.
96. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. *Nat Genet*. 2009;41:544–52.
97. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. *Oncogene*. 2003;22:3113–22.
98. Bircak A, Ahrenkiel V, Zeuthen J, Hou-Jensen K, Guldberg P. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. *J Invest Dermatol*. 2000;114:277–80.
99. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. *Am J Pathol*. 2000;157:1123–8.

100. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, et al. Epigenetic silencing of the PTEN gene in melanoma. *Cancer Res.* 2006;66:6546–52.
101. Dong Y, Richards JA, Gupta R, Aung PP, Emley A, Kluger Y, et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response. *Oncogene.* 2014;33:4632–42.
102. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. *Nat Med.* 2007;13:84–8.
103. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. *Cancer Discov.* 2018;8:1156–75.
104. Sepulveda C, Palomo I, Fuentes E. Role of adenosine A2b receptor overexpression in tumor progression. *Life Sci.* 2016;166:92–9.
105. Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. *Cancer Immunol Res.* 2015;3:506–17.
106. Wang HM, Zhang XH, Feng MM, Qiao YJ, Ye LQ, Chen J, et al. Interleukin-35 suppresses the antitumor activity of T cells in patients with non-small cell lung cancer. *Cell Physiol Biochem.* 2018;47:2407–19.
107. Li S, Wang Z, Li XJ. Notch signaling pathway suppresses CD8(+) T cells activity in patients with lung adenocarcinoma. *Int Immunopharmacol.* 2018;63:129–36.
108. Akbay EA, Koyama S, Liu Y, Dries R, Bufe LE, Silkes M, et al. Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade. *J Thorac Oncol.* 2017;12:1268–79.
109. George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. *Immunity.* 2017;46:197–204.
110. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. *Nat Rev Clin Oncol.* 2018;15:325–40.
111. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. *Cancer Cell.* 2014;26:605–22.
112. Liang CT, Guo WH, Tan L, He YB, Xiong F, Zhang SS, et al. Hypoxia-inducible factor-1: a key protein for cells adapting to changes in oxygen supply. *Prog Biochem Biophys.* 2019;46:1041–9.
113. Zhu H, Gu Y, Xue Y, Yuan M, Cao X, Liu Q. CXCR2(+) MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion. *Oncotarget.* 2017;8:114554–67.
114. Zhao J, Wen X, Tian L, Li T, Xu C, Wen X, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. *Nat Commun.* 2019;10:899.
115. Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. *Clin Cancer Res.* 2016;22:1856–64.
116. Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. *Cell.* 2016;167:1540–54 e1512.
117. Konen JM, Rodriguez BL, Fradette JJ, Gibson L, Davis D, Minelli R, et al. Ntrk1 promotes resistance to PD-1 checkpoint blockade in mesenchymal Kras/p53 mutant lung cancer. *Cancers (Basel).* 2019;11:462.
118. Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, et al. Adaptive plasticity of IL-10(+) and IL-35(+) Treg cells cooperatively promotes tumor T cell exhaustion. *Nat Immunol.* 2019;20:724–35.
119. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature.* 2018;560:382–6.
120. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. *Cell Rep.* 2017;19:1189–201.
121. Kowanetz M, Zou W, Gettinger SN, Koepfen H, Kockx M, Schmid P, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). *Proc Natl Acad Sci U S A.* 2018;115:E10119–26.
122. Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. *Oncoimmunology.* 2018;7:e1438106.
123. Jia L, Xi Q, Wang H, Zhang Z, Liu H, Cheng Y, et al. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. *Biochem Biophys Res Commun.* 2017;488:425–31.
124. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. *Cancer Discov.* 2017;7:188–201.
125. Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadler N, et al. Acquired IFN γ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. *Nat Commun.* 2017;8:15440.
126. Deng X, Xiong F, Li X, Xiang B, Li Z, Wu X, et al. Application of atomic force microscopy in cancer research. *J Nanobiotechnol.* 2018;16:102.
127. Fish EN, Platanias LC. Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. *Mol Cancer Res.* 2014;12:1691–703.
128. Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank KG, Paschen A. Tumor CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance. *J Natl Cancer Inst.* 2018;110:677–81.
129. Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. *J Thorac Oncol.* 2015;10:910–23.
130. Ikeda S, Okamoto T, Okano S, Umemoto Y, Tagawa T, Morodomi Y, et al. PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer. *J Thorac Oncol.* 2016;11:62–71.
131. Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Hazarian SR, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. *Cancer Res.* 2016;76:227–38.
132. Wang W, Zhou R, Wu Y, Liu Y, Su W, Xiong W, et al. PVT1 promotes cancer progression via MicroRNAs. *Front Oncol.* 2019;9:609.
133. Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, et al. Natural killer group 2D receptor and its ligands in cancer immune escape. *Mol Cancer.* 2019;18:29.
134. Fan C, Tu C, Qi P, Guo C, Xiang B, Zhou M, et al. GPC6 promotes cell proliferation, migration, and invasion in nasopharyngeal carcinoma. *J Cancer.* 2019;10:3926–32.
135. Mo Y, Wang Y, Xiong F, Ge X, Li Z, Li X, et al. Proteomic analysis of the molecular mechanism of lovastatin inhibiting the growth of nasopharyngeal carcinoma cells. *J Cancer.* 2019;10:2342–9.
136. Mo Y, Wang Y, Zhang L, Yang L, Zhou M, Li X, et al. The role of Wnt signaling pathway in tumor metabolic reprogramming. *J Cancer.* 2019;10:3789–97.
137. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for Cancer immunotherapy: mechanism, combinations, and clinical outcome. *Front Pharmacol.* 2017;8:561.
138. Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. *Clin Cancer Res.* 2018;24:896–905.
139. Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. *Cell Rep.* 2017;20:854–67.
140. Toyokawa G, Takada K, Tagawa T, Hamamoto R, Yamada Y, Shimokawa M, et al. A positive correlation between the EZH2 and PD-L1 expression in resected lung adenocarcinomas. *Ann Thorac Surg.* 2019;107:393–400.
141. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. *Cancer Discov.* 2016;6:827–37.
142. Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, et al. Deubiquitination and stabilization of PD-L1 by CSN5. *Cancer Cell.* 2016;30:925–39.
143. Wang S, Li J, Xie J, Liu F, Duan Y, Wu Y, et al. Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin beta4/SNAI1/SIRT3 signaling pathway. *Oncogene.* 2018;37:4164–80.
144. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. *J Exp Med.* 2005;202:1691–701.
145. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. *Annu Rev Immunol.* 2013;31:51–72.
146. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. *Nat Rev Cancer.* 2012;12:860–75.
147. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. *Nat Med.* 2007;13:54–61.

148. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. *Oncogene*. 2010;29:482–91.
149. Kim SS, Harford JB, Moghe M, Rait A, Chang EH. Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor. *Oncoimmunology*. 2018;7:e1484982.
150. Kim SS, Rait A, Kim E, Pirolo KF, Chang EH. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. *Nanomedicine*. 2015;11:301–11.
151. Kim SS, Rait A, Kim E, Pirolo KF, Nishida M, Farkas N, et al. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. *ACS Nano*. 2014;8:5494–514.
152. Munoz-Fontela C, Mandinova A, Aaronson SA, Lee SW. Emerging roles of p53 and other tumour-suppressor genes in immune regulation. *Nat Rev Immunol*. 2016;16:741–50.
153. Zhou H, Forveille S, Sauvat A, Yamazaki T, Senovilla L, Ma Y, et al. The oncolytic peptide LTX-315 triggers immunogenic cell death. *Cell Death Dis*. 2016;7:e2134.
154. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. *Clin Cancer Res*. 2017;23:2255–66.
155. Flores CT, Wildes TJ, Drake JA, Moore GL, Dean BD, Abraham RS, et al. Lin(−)CCR2(+) hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade. *Nat Commun*. 2018;9:4313.
156. Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, et al. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. *Leukemia*. 2018;32:1932–47.
157. Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. *Clin Cancer Res*. 2014;20:3818–29.
158. Soldevilla MM, Villanueva H, Martinez-Velez N, Meraviglia-Crivelli D, Alonso MM, Cebollero J, et al. Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors. *Oncoimmunology*. 2018;7:e1450711.
159. Knudson KM, Hicks KC, Alter S, Schlom J, Gameiro SR. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. *J Immunother Cancer*. 2019;7:82.
160. Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, et al. CD96 is an immune checkpoint that regulates CD8(+) T-cell antitumor function. *Cancer Immunol Res*. 2019;7:559–71.
161. Lian S, Xie R, Ye Y, Lu Y, Cheng Y, Xie X, et al. Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. *Sci Rep*. 2019;9:4532.
162. Lian S, Xie R, Ye Y, Xie X, Li S, Lu Y, et al. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. *EBioMedicine*. 2019;42:281–95.
163. Rodriguez-Ruiz ME, Rodriguez I, Mayorga L, Labiano T, Barbes B, Etxeberria I, et al. TGFbeta blockade enhances radiotherapy Abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies. *Mol Cancer Ther*. 2019;18:621–31.
164. Ahern E, Harjunpaa H, O'Donnell JS, Allen S, Dougall WC, Teng MWL, et al. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. *Oncoimmunology*. 2018;7:e1431088.
165. Jing CY, Fu YP, Yi Y, Zhang MX, Zheng SS, Huang JL, et al. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. *J Immunother Cancer*. 2019;7:77.
166. Greenberg SA, Kong SW, Thompson E, Gulla SV. Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models. *Oncotarget*. 2019;10:1399–406.
167. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, et al. Clonal deletion of tumor-specific T cells by interferon-gamma confers therapeutic resistance to combination immune checkpoint blockade. *Immunity*. 2019;50:477–92 e478.
168. Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. *Sci Transl Med*. 2014;6:237ra267.
169. Wang Y, Zhang X, Yang L, Xue J, Hu G. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. *J Bone Oncol*. 2018;11:27–32.
170. Chatterjee S, Chakraborty P, Daenthanasannak A, Iamsawat S, Andrejeva G, Luevano LA, et al. Targeting PIM kinase with PD1 inhibition improves immunotherapeutic antitumor T-cell response. *Clin Cancer Res*. 2019;25:1036–49.
171. Kordbacheh T, Honeychurch J, Blackhall F, Faivre-Finn C, Illidge T. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. *Ann Oncol*. 2018;29:301–10.
172. Yu S, Cai L, Lin F, Wu X, Zhang C, Liu X, et al. Durable response after combination of concurrent chemoradiotherapy and anti-PD-1 therapy in HER2-negative advanced gastric adenocarcinoma: a case report. *Oncotargets Ther*. 2019;12:7691–8.
173. La Rocca E, Dispinzieri M, Lozza L, Mariani G, Di Cosimo S, Gennaro M, et al. Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer. *Med Oncol*. 2018;36:4.
174. Finazzi T, Rordorf T, Ikenberg K, Huber GF, Guckenberger M, Garcia Schueler HJ. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. *BMC Cancer*. 2018;18:395.
175. Ji D, Yi H, Zhang D, Zhan T, Li Z, Li M, et al. Somatic mutations and immune alternation in rectal cancer following neoadjuvant chemoradiotherapy. *Cancer Immunol Res*. 2018;6:1401–16.
176. Hettich M, Lahoti J, Prasad S, Niedermann G. Checkpoint antibodies but not T cell-recruiting diabodies effectively synergize with TIL-inducing gamma-irradiation. *Cancer Res*. 2016;76:4673–83.
177. Xie G, Gu D, Zhang L, Chen S, Wu D. A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma. *Cancer Biol Ther*. 2017;18:547–51.
178. Schvartsman G, Peng SA, Bis G, Lee JJ, Benveniste MFK, Zhang J, et al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. *Lung Cancer*. 2017;112:90–5.
179. Teng F, Kong L, Meng X, Yang J, Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. *Cancer Lett*. 2015;365:23–9.
180. Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gasparo A, et al. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy. *J Immunother Cancer*. 2019;7:10.
181. Rodel F, Frey B, Gaipal U, Keilholz L, Fournier C, Manda K, et al. Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical application. *Curr Med Chem*. 2012;19:1741–50.
182. Lu CS, Liu JH. Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: three case reports. *Medicine (Baltimore)*. 2017;96:e5747.
183. Galvin KC, Conroy MJ, Doyle SL, Dunne MR, Fahey R, Foley E, et al. Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma. *Cancer Lett*. 2018;418:230–8.
184. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus placebo in resected stage III melanoma. *N Engl J Med*. 2018;378:1789–801.
185. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruner G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. *Ann Oncol*. 2015;26:259–71.
186. Rehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V, Mani NL, et al. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. *Mod Pathol*. 2017;30:340–9.
187. Smith J, Robida MD, Acosta K, Vennapusa B, Mistry A, Martin G, et al. Quantitative and qualitative characterization of two PD-L1 clones: SP263 and E1L3N. *Diagn Pathol*. 2016;11:44.
188. Morales-Betanzos CA, Lee H, Gonzalez Ericsson PI, Balko JM, Johnson DB, Zimmerman LJ, et al. Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. *Mol Cell Proteomics*. 2017;16:1705–17.
189. Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. *Cancer Cell*. 2019;36:168–178.e4.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.